Title:
PSMA-TARGETING NUCLIDE/FLUORESCENT BIMODAL LIGAND AND MOLECULAR PROBE, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/087734
Kind Code:
A1
Abstract:
Disclosed are a PSMA-targeting nuclide/fluorescent bimodal ligand and molecular probe, and the use thereof. The PSMA-targeting bimodal molecular probe is designed and synthesized by using dencichine-ureido as a PSMA-targeting structure, and by means of optimizing a linker and then carrying out nuclide/fluorescence dual-functionalization. The nuclide/fluorescent bimodal molecular probe can be used for preoperative PET/CT imaging to formulate a surgical operation route, and fluorescence guidance is carried out during surgery so as to carry out tumor positioning and boundary division.
More Like This:
Inventors:
YANG XING (CN)
TIAN JIE (CN)
ZHANG NING (CN)
HU ZHENHUA (CN)
DUAN XIAOJIANG (CN)
LI YUAN (CN)
TIAN JIE (CN)
ZHANG NING (CN)
HU ZHENHUA (CN)
DUAN XIAOJIANG (CN)
LI YUAN (CN)
Application Number:
PCT/CN2022/103339
Publication Date:
May 25, 2023
Filing Date:
July 01, 2022
Export Citation:
Assignee:
UNIV PEKING FIRST HOSPITAL (CN)
International Classes:
C07D403/14; A61K49/00; A61K51/04; C09K11/06
Foreign References:
| CN114014843A | 2022-02-08 | |||
| CN112062695A | 2020-12-11 | |||
| CN112574280A | 2021-03-30 | |||
| CN113166054A | 2021-07-23 | |||
| CN105636924A | 2016-06-01 | |||
| CN110199195A | 2019-09-03 | |||
| CN111233758A | 2020-06-05 | |||
| CN112851637A | 2021-05-28 | |||
| CN112321673A | 2021-02-05 | |||
| CN112898270A | 2021-06-04 | |||
| US20160263249A1 | 2016-09-15 |
Attorney, Agent or Firm:
BEIJING SICHUANG DACHENG INTELLECTUAL PROPERTY AGENCY CO., LTD. (CN)
Download PDF: